InVivo Biosystems Raises $3M for CRISPR Research and Welcomes New Board Chairman
Summary
The Eugene, Oregon-based company has secured a notable $3 million investment, a collaborative effort led by Rogue Venture Partners with significant contributions from Portland Seed Fund, ONAMI, and Launch Oregon. His expertise is expected to be pivotal in steering the companys strategic decisions.The timing of these developments coincides with a growing global recognition of the potential of CRISPR technology in transforming therapeutic outcomes. Matt Beaudet, CEO of InVivo Biosystems, regards the investment and leadership addition as key catalysts for the companys innovative pursuits in the upcoming year. With InVivo Biosystems core intellectual property and CRISPR expertise, the company is poised to play a critical role in expediting drug discovery processes, offering efficient and cost-effective solutions for biotech and pharmaceutical collaborations.Recent technological advancements and intellectual property acquisitions at InVivo Biosystems further underscore the companys commitment to innovation in this field. This system promises to enhance the management of research facilities and improve the reproducibility of scientific results, particularly in genome-edited fish models that replicate human diseases.Moreover, InVivo Biosystems has obtained an exclusive license for MIC-Drop, a pioneering CRISPR technology, from the University of Utah.